Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ALBI Grade (Liver)ASTCT GradingATA Thyroid RiskBCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPICML ELTS ScoreCNS-IPICTCAE v5.0Calvert FormulaDIPSS-Plus (Myelofibrosis)Deauville ScoreEAU NMIBC RiskECOG Performance StatusELN 2022 Risk (AML)ELN CML MilestonesFIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2Fleischner 2017 GuidelinesFong Clinical Risk ScoreHCT-CI (Sorror Score)HPV/p16 OropharynxIGCCCG Risk (Testicular)IMDC (Heng) CriteriaIMWG Myeloma FrailtyIPSS-M (Molecular MDS)ISUP Grade GroupsKarnofsky Status (KPS)Khorana ScoreLugano ClassificationLung-RADS v2022MIPI-b (Biological)MRD Assessment FrameworkMSI/MMR InterpretationMayo 20/2/20 (SMM)NCCN Prostate RiskNCCN-IPI (DLBCL)NSCLC GPAOncotype DX RecurrenceOpioid EquianalgesicPD-L1 TPS InterpretationPERCIST 2.0PREDICT v3.0Platinum-Free IntervalR2-ISS (Revised 2)RANO 2.0RCB (Residual Cancer Burden)RECIST 1.1ROMA ScoreSAVER ScoreSINS ScoreSLiM-CRAB CriteriaSedlis/Peters CriteriaTNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AMLZ0011 EligibilityiRECISTiwCLL 2018 ResponsemRECIST (HCC)mRENAL ScoremrTRG (Rectal MRI)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

DiabetologiaJun 6, 2026
Time-restricted eating versus dietetic guidance on glycaemic outcomes in adults at risk of type 2 diabetes: a non-inferiority randomised clinical trial

Clinical Context

We think this might be relevant to the clinical guidance for SAVER Score (Serious Adverse Event Risk).

JAMAJun 2, 2026
Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke

Clinical Context

We think this might be relevant to the clinical guidance for SAVER Score (Serious Adverse Event Risk).

Drug SafetyJun 2, 2026
Incidence of Naloxone-Use Before and After Implementing Opioid Safety Measures for Patients Hospitalised on General Wards in a Swiss University Hospital

Clinical Context

We think this might be relevant to the clinical guidance for SAVER Score (Serious Adverse Event Risk).

SAVER Score

SAVER SCOREirAE Severity Risk Assessment

Prognostic Tier

Model Context

The SAVER score integrates baseline clinical data (e.g., age, BMI, lab values) to predict the likelihood of Grade ≥ 3 immune-related adverse events during checkpoint inhibitor therapy.

Risk Profile

Low Risk

Clinical Strategy

Low risk for high-grade immune-related adverse events. Routine monitoring as per standard protocol.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Patients with advanced solid tumors initiating therapy with PD-1/PD-L1 inhibitors or CTLA-4 inhibitors.
Used to determine the frequency of outpatient monitoring and lab testing.
Aids in the decision-making process for patients with marginal performance status or significant autoimmune comorbidities.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the CTCAE v5.0, ASTCT Grading or the Khorana Score to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Oncology Tools

CTCAE v5.0
ASTCT Grading
Khorana Score
iRECIST
EAU NMIBC Risk
MIPI-b
FIGO 2023
NCCN-IPI
RECIST 1.1
TNM 8th Ed
Oncology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.